Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
A Comparison of the Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy Versus Varenicline Alone for Smoking Cessation: a Pilot Study
Sponsor: Pfizer
Terminated
Following the Chantix recall, Pfizer stopped providing medication for the study and and new study enrollments were discontinued.
Listed as NCT03722966, this PHASE2 trial focuses on Smoking Cessation and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 16 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2022 — Mar 2024 [monthly]
Terminated PHASE2
-
Mar 2022 — Nov 2022 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
▶ Show 11 earlier versions
-
Nov 2021 — Mar 2022 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
May 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — May 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2018 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
- University of Oklahoma
For direct contact, visit the study record on ClinicalTrials.gov .